Consistent results were found in subgroup analyses stratified by eGFR; HbA1c; presence of cardiovascular disease, proteinuria, or diabetic complications; use of metformin, insulin, SGLT2is, ACEis, or ARBs; previous GLP-1 RA treatment; potential indications; LDL cholesterol level; and BMI. This evidence concerns the gene GLP1R and cardiovascular disorder.